<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-7523</journal-id>
<journal-title><![CDATA[Revista Cubana de Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Cuban de Med]]></abbrev-journal-title>
<issn>0034-7523</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-75232025000100027</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Factores predictivos de respuesta del carcinoma basocelular al tratamiento con una mezcla de interferones]]></article-title>
<article-title xml:lang="en"><![CDATA[Response Predictive Factors of Basal Cell Carcinoma to Treatment with a Mixture of Interferons]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fernández Martori]]></surname>
<given-names><![CDATA[Meilyn]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Soler Cárdenas]]></surname>
<given-names><![CDATA[Silvio Faustino]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bacallao Gallestey]]></surname>
<given-names><![CDATA[Jorge]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Policlinico Universitario Mario Muñoz Monroy  ]]></institution>
<addr-line><![CDATA[ Matanzas]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Ciencias Médicas  ]]></institution>
<addr-line><![CDATA[ Matanzas]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Centro de investigación y Referencia de la Aterosclerosis  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<volume>64</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0034-75232025000100027&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0034-75232025000100027&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0034-75232025000100027&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  Para el carcinoma basocelular existen protocolos terapéuticos cuya elección depende de los factores de riesgo. El HeberFERON se incorporó a las normas cubanas para esta variante de cáncer de piel, sin embargo, su indicación no está estratificada.  Objetivo:  Identificar los factores predictivos de respuesta a esta opción de tratamiento.  Métodos:  Se realizó un estudio descriptivo y longitudinal, en el Policlínico Dr. Carlos J. Finlay en el período comprendido entre enero de 2017 y diciembre de 2023. La muestra estuvo constituida por 126 pacientes con lesiones únicas o múltiples, que cumplieron con los criterios de inclusión y exclusión. Las variables del estudio fueron edad, sexo, antecedentes de cáncer de piel, fototipo cutáneo, presencia de hipertensión arterial, tipo de tumor, subtipo histológico, tiempo de evolución, diámetro mayor y la respuesta clínica al tratamiento. Se realizó un análisis univariado mediante las frecuencias absolutas y relativas, y el coeficiente de contingencia. El análisis multivariado se basó en un árbol de clasificación y de regresión.  Resultados: De las variables epidemiológicas, la edad y la hipertensión arterial resultaron ser una asociación moderada a la respuesta. El subtipo histológico, el tamaño tumoral y el tiempo de evolución fueron las variables clínicas e histológicas con mayor asociación con la respuesta. El árbol de clasificación permitió realizar una estratificación preliminar en alto, intermedio y bajo riesgo con buena capacidad predictiva.  Conclusiones:  La edad de los pacientes, el tiempo de evolución y el tamaño tumoral constituyeron los factores predictivos de la respuesta al HeberFERON del carcinoma basocelular.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  For basal cell carcinoma there are therapeutic protocols whose choice depends on the risk factors. HeberFERON was incorporated into the Cuban standards for this variant of skin cancer, however, its indication is not stratified.  Objective:  To identify the response predictive factors to this treatment option.  Methods:  A descriptive and longitudinal study was carried out at Dr. Carlos J. Finlay Polyclinic in the period from January 2017 to December 2023. The sample consisted of 126 patients with single or multiple lesions, who met the inclusion and exclusion criteria. The study variables were age, sex, history of skin cancer, skin phototype, presence of arterial hypertension, tumor type, histological subtype, evolution time, largest diameter and clinical response to treatment. Univariate analysis was performed using absolute and relative frequencies and the contingency coefficient. Multivariate analysis was based on a classification and regression tree.  Results:  Out of the epidemiological variables, age and arterial hypertension were found to be moderately associated with response. Histological subtype, tumor size and evolution time were the clinical and histological variables with the greatest association with response. The classification tree allowed a preliminary stratification into high, intermediate and low risk with good predictive capacity.  Conclusions:  The age of the patients, the evolution time and the tumor size were the predictive factors of the response to HeberFERON in basal cell carcinoma.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[carcinoma basocelular]]></kwd>
<kwd lng="es"><![CDATA[interferon alfa]]></kwd>
<kwd lng="es"><![CDATA[interferon gamma]]></kwd>
<kwd lng="es"><![CDATA[factores predictivos]]></kwd>
<kwd lng="es"><![CDATA[respuesta clínica]]></kwd>
<kwd lng="en"><![CDATA[basal cell carcinoma]]></kwd>
<kwd lng="en"><![CDATA[interferon alpha]]></kwd>
<kwd lng="en"><![CDATA[interferon gamma]]></kwd>
<kwd lng="en"><![CDATA[predictive factors]]></kwd>
<kwd lng="en"><![CDATA[clinical response]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública (CUBA)</collab>
<source><![CDATA[Sección Independiente de Control del Cáncer. Prevención, diagnóstico y tratamiento del cáncer de piel]]></source>
<year>2023</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Venables]]></surname>
<given-names><![CDATA[ZC]]></given-names>
</name>
<name>
<surname><![CDATA[Nijsten]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[KF]]></given-names>
</name>
<name>
<surname><![CDATA[Autier]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Broggio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Deas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K. 2013-15: a cohort study]]></article-title>
<source><![CDATA[British Journal of Dermatology]]></source>
<year>2019</year>
<volume>181</volume>
<page-range>474-82</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salsavilca]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<source><![CDATA[Características clínicas e histopatológicas de los tumores malignos de piel más frecuentes en el hospital II Essalud Pucallpa durante el período 2014 al 2018]]></source>
<year>2021</year>
<publisher-loc><![CDATA[Ucayali, Perú ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Nacional de Ucayali]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández-Martínez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera-Lira]]></surname>
<given-names><![CDATA[FP]]></given-names>
</name>
<name>
<surname><![CDATA[Toussaint-Caire]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Roldán-Marín]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoma basocelular superficial: un enfoque diagnóstico y terapéutico distinto]]></article-title>
<source><![CDATA[Dermatología CMQ]]></source>
<year>2022</year>
<volume>20</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>431-5</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García-Alfonso]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores pronósticos y predictivos de respuesta de utilidad clínica]]></article-title>
<source><![CDATA[Oncología]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology</collab>
<source><![CDATA[Basal Cell Skin Cancer Version 1. 2022]]></source>
<year>2021</year>
<publisher-loc><![CDATA[USA ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology</collab>
<source><![CDATA[Basal Cell Skin Cancer Version 2. 2024]]></source>
<year>2023</year>
<publisher-loc><![CDATA[USA ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cameron]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hibler]]></surname>
<given-names><![CDATA[BP]]></given-names>
</name>
<name>
<surname><![CDATA[Barker]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Mori]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Córdoba]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Basal cell carcinoma. Contemporary approaches to diagnosis, treatment, and prevention]]></article-title>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2019</year>
<volume>80</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>303-17</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peris]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Fargnoli]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Garbe]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kaufmann]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bastholt]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Seguin]]></surname>
<given-names><![CDATA[NB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and treatment of basal cell carcinoma: European consensus based interdisciplinary]]></article-title>
<source><![CDATA[European Journal of Cancer]]></source>
<year>2019</year>
<volume>118</volume>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vílchez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Borregón]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Barchino]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Ruíz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Palacios]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Soria]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoma basocelular cutáneo: diagnóstico y tratamiento en atención especializada dermatológica. Guía de Práctica Clínica de la AEDV]]></article-title>
<source><![CDATA[Actas Dermosifiliogr]]></source>
<year>2020</year>
<volume>111</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<collab>Instituto Mexicano del Seguro Social</collab>
<source><![CDATA[Dirección de Prestaciones Médicas. Guía de Práctica Clínica. Diagnóstico y Tratamiento del carcinoma Basocelular]]></source>
<year>2019</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[CENETEC]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Requena]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sanmartin]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoma basocelular histológicamente agresivo con especial atención a la infiltración galeal del cuero cabelludo]]></article-title>
<source><![CDATA[ACTAS Dermo-Sifiliográficas]]></source>
<year>2022</year>
<volume>113</volume>
<page-range>575-82</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ongaratto-Barazzetti]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ongaratto-Barazzetti]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
<name>
<surname><![CDATA[Thomé-Cavalheiro]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bins-Ely]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Holthausen-Nunes]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Nunes-de Faria]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quality of life and clinical and demographic characteristics of patients with cutaneous squamous cell carcinoma submitted to tumor resection by double-bladed scalpel]]></article-title>
<source><![CDATA[An Bras Dermatol]]></source>
<year>2019</year>
<volume>94</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>304-12</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coile]]></surname>
<given-names><![CDATA[LV]]></given-names>
</name>
<name>
<surname><![CDATA[Verhaeghe]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ongenae]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Destrooper]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mohamadi]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Brochez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The therapeutic dilemma of basal cell carcinoma in older adults: A review of the current literature]]></article-title>
<source><![CDATA[Journal of Geriatric Oncology]]></source>
<year>2023</year>
<volume>14</volume>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[OM]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Steele]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wilmas]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Aboul-Fettouh]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Burns]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advances in Management and Therapeutics of Cutaneous Basal Cell Carcinoma]]></article-title>
<source><![CDATA[Cancers (Basel)]]></source>
<year>2022</year>
<volume>14</volume>
<numero>15</numero>
<issue>15</issue>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<collab>CECMED</collab>
<source><![CDATA[HEBERFERON® (Interferón alfa 2b hu-rec + Interferón gamma hu-rec)]]></source>
<year>2022</year>
<publisher-loc><![CDATA[La Habana, Cuba ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Salud Pública]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Carpio]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fardales]]></surname>
<given-names><![CDATA[VE]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Arias]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Brito]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Long-term follow-up of patients with high-risk facial basal cell carcinoma treated with interferon]]></source>
<year>2023</year>
<publisher-name><![CDATA[Anais Brasileiros de Dermatología]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez-Suárez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Roben-Aguilar]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes-Acosta]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[García-Vega]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Vega- Abascal]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Linares]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Basal Cell Carcinoma Treated with HeberFERON. A Real World Retrospective Study]]></article-title>
<source><![CDATA[Clin Oncol]]></source>
<year>2021</year>
<volume>6</volume>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sotolongo-Díaz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Vidal-Suárez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bello-Rivero]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Montes de Oca-Álvarez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nájara-Pérez]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Armas-Morell]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectividad del HeberFERON® en el tratamiento del carcinoma basocelular del dorso de la nariz]]></article-title>
<source><![CDATA[Revista Médica Electrónica MediCiego]]></source>
<year>2021</year>
<volume>27</volume>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez-Linares]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Fando]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-González]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[González-Pérez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bello-Rivero]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento del carcinoma basocelular de la nariz con una combinación de interferones Alpha-2b y Gamma]]></article-title>
<source><![CDATA[Rev Haban Cienc Méd]]></source>
<year>2022</year>
<volume>21</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flores]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Morán]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Betancourt]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Criterios de Evaluación en Tumores Sólidos 1.1 (RECIST 1.1) en pacientes con cáncer primario y/o metastásico o enfermedad metastásica recurrente]]></article-title>
<source><![CDATA[Rev S Científica]]></source>
<year>2018</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<collab>World Medical Assocition Declaration of Helsinki</collab>
<article-title xml:lang=""><![CDATA[Ethical Principles for Medical Research Involving Human Subjects]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2013</year>
<volume>310</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>1-95</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Pupo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Manganelly-Fonseca]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Tablada- Robinet]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Jacas-Portuondo]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Girón-Maturell]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilidad del HeberFERON en pacientes con carcinoma basocelular]]></article-title>
<source><![CDATA[MEDISAN]]></source>
<year>2021</year>
<volume>25</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Río-Ysla]]></surname>
<given-names><![CDATA[MB del]]></given-names>
</name>
<name>
<surname><![CDATA[Abreu-Rivero]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Matos-Pelegrin]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz-García]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Resultado terapéutico del uso del HeberFERON en pacientes con carcinoma basocelular en la región de la cara]]></article-title>
<source><![CDATA[Revista Médica Electrónica de Ciego de Ávila]]></source>
<year>2020</year>
<volume>26</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez-Rosales]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fonseca-Núñez]]></surname>
<given-names><![CDATA[YD]]></given-names>
</name>
<name>
<surname><![CDATA[Fuentes-Gómez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mojena-Hernández]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Tamayo-Ladrón de Guevara]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectividad del HeberFERON en el tratamiento del carcinoma basocelular]]></article-title>
<source><![CDATA[Multimed]]></source>
<year>2023</year>
<numero>27</numero>
<issue>27</issue>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez-Fonseca]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[de la Rosa-Santana]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[López-Wilson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Santiesteban-Puerta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrera-Pérez]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento con HeberFERON en pacientes con carcinoma basocelular del Hospital Docente Clínico Quirúrgico &#8220;Dr. Miguel Enríquez&#8221;, La Habana]]></article-title>
<source><![CDATA[Gac Med Est]]></source>
<year>2020</year>
<volume>1</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bermúdez-Sañudo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Monzón-Díaz]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Piña-Rodríguez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Darias-Domínguez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Resultados del uso de HeberFERON en pacientes con carcinoma basocelular de alto riesgo en Matanzas]]></article-title>
<source><![CDATA[Rev Méd Electrón]]></source>
<year>2023</year>
<volume>45</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fania]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Didona]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Morese]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Campana]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Coco]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Di Pietro]]></surname>
<given-names><![CDATA[FR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Basal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches Biomedicines]]></article-title>
<source><![CDATA[]]></source>
<year>2020</year>
<volume>8</volume>
<numero>11</numero>
<issue>11</issue>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fija&#322;kowska]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bonczar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jastrz&#281;bski]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ostrowski]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Antoszewski]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kozie]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Growth rate of basal cell carcinoma: a meta-analysis and systematic review]]></article-title>
<source><![CDATA[Adv Dermatol Allergol]]></source>
<year>2023</year>
<volume>XL</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>220-4</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez-Linares]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrera-Naranjo]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Amaró-Garrido]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Tamayo-Pérez]]></surname>
<given-names><![CDATA[OM]]></given-names>
</name>
<name>
<surname><![CDATA[Casanova-Cruz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bello-Rivero]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoma basocelular de la piel cabelluda tratado con HeberFERON. Seguimiento clínico, ecográfico e histopatológico]]></article-title>
<source><![CDATA[Gac. Méd. Espirit]]></source>
<year>2023</year>
<volume>25</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Betti]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Moneghini]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mapelli]]></surname>
<given-names><![CDATA[ET]]></given-names>
</name>
<name>
<surname><![CDATA[Bulfamante]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cerri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Growth Rate of Different Basal Cell Carcinoma Subtypes]]></article-title>
<source><![CDATA[European Journal of Dermatology]]></source>
<year>2017</year>
<volume>27</volume>
<page-range>544-5</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Avilés-Jurado]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Comparación de los factores pronósticos en pacientes con carcinoma de cabeza y cuello a partir de dos metodologías diferentes: análisis multivariante versus análisis de partición recursiva]]></source>
<year>2010</year>
<publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Autónoma de Barcelona]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
